Compare FONR & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FONR | OVID |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 117.5M |
| IPO Year | 1995 | 2017 |
| Metric | FONR | OVID |
|---|---|---|
| Price | $18.54 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 66.4K | ★ 1.3M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $104,351,318.00 | $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.02 | ★ N/A |
| Revenue Growth | ★ 1.43 | N/A |
| 52 Week Low | $12.00 | $0.24 |
| 52 Week High | $18.86 | $2.01 |
| Indicator | FONR | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 61.60 | 54.50 |
| Support Level | $18.49 | $1.43 |
| Resistance Level | $18.73 | $1.70 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 20.92 | 85.39 |
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.